Next-generation proteasome inhibitor oprozomib synergizes with modulators of the unfolded protein response to suppress hepatocellular carcinoma

Hepatocellular carcinoma (HCC) responds poorly to conventional systemic therapies. The first-in-class proteasome inhibitor bortezomib has been approved in clinical use for hematologic malignancies and has shown modest activity in solid tumors, including HCC. However, a considerable proportion of pat...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Oncotarget
Main Authors: Vandewynckel, Yves-Paul, Coucke, Céline, Laukens, Debby, Devisscher, Lindsey, Paridaens, Annelies, Bogaerts, Eliene, Vandierendonck, Astrid, Raevens, Sarah, Verhelst, Xavier, Van Steenkiste, Christophe, Libbrecht, Louis, Geerts, Anja, Van Vlierberghe, Hans
Format: Artigo
Sprog:Inglês
Udgivet: Impact Journals LLC 2016
Fag:
Research Paper
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5085204/
https://ncbi.nlm.nih.gov/pubmed/27167000
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.9222
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker